Related Experiment Video
Updated: May 2, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
8.0K
Is there clinical value to prognostic signatures in early-stage NSCLC?
Paul A Bunn1, Fred R Hirsch, Dara L Aisner
1Authors' Affiliations: Division of Medical Oncology, Departments of Medicine and Pathology, University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado.
Abstract:
pAMPK and pmTOR favorably predicted outcome in early non-small cell lung cancer (NSCLC). The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein immunohistochemistry is unlikely to be clinically useful, and numerous efforts to create predictive models to select resected patients for therapy have been unsuccessful.
